{"name":"Astellas Pharma Global Development, Inc.","slug":"astellas-pharma-global-development-inc","ticker":"","exchange":"","domain":"astellaspharmaglobaldevelopment.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":26,"colorKey":"oncology","drugs":[{"name":"Tacrolimus immediate release","genericName":"Tacrolimus immediate release","slug":"tacrolimus-immediate-release","indication":"Other","status":"marketed"},{"name":"AGS15E","genericName":"AGS15E","slug":"ags15e","indication":"Other","status":"phase_1"},{"name":"ASP0892","genericName":"ASP0892","slug":"asp0892","indication":"Other","status":"phase_1"},{"name":"ASP1240","genericName":"ASP1240","slug":"asp1240","indication":"Other","status":"phase_1"},{"name":"ASP5354","genericName":"ASP5354","slug":"asp5354","indication":"Other","status":"phase_1"},{"name":"ASP7517","genericName":"ASP7517","slug":"asp7517","indication":"Other","status":"phase_1"},{"name":"ASP8082","genericName":"ASP8082","slug":"asp8082","indication":"Other","status":"phase_1"},{"name":"ASP9801","genericName":"ASP9801","slug":"asp9801","indication":"Other","status":"phase_1"},{"name":"isavuconazonium sulfate - oral","genericName":"isavuconazonium sulfate - oral","slug":"isavuconazonium-sulfate-oral","indication":"Other","status":"phase_1"},{"name":"14C-labeled gilteritinib","genericName":"14C-labeled gilteritinib","slug":"14c-labeled-gilteritinib","indication":"Other","status":"phase_1"},{"name":"ASP015K IR","genericName":"ASP015K IR","slug":"asp015k-ir","indication":"Other","status":"phase_1"},{"name":"ASP0892 Intradermal","genericName":"ASP0892 Intradermal","slug":"asp0892-intradermal","indication":"Other","status":"phase_1"},{"name":"ASP0892 Intramuscular","genericName":"ASP0892 Intramuscular","slug":"asp0892-intramuscular","indication":"Other","status":"phase_1"},{"name":"ASP1002","genericName":"ASP1002","slug":"asp1002","indication":"Other","status":"phase_1"},{"name":"ASP1570","genericName":"ASP1570","slug":"asp1570","indication":"Other","status":"phase_1"},{"name":"ASP1617","genericName":"ASP1617","slug":"asp1617","indication":"Other","status":"phase_1"},{"name":"ASP2138","genericName":"ASP2138","slug":"asp2138","indication":"Other","status":"phase_1"},{"name":"ASP2390","genericName":"ASP2390","slug":"asp2390","indication":"Other","status":"phase_1"},{"name":"ASP2408","genericName":"ASP2408","slug":"asp2408","indication":"Other","status":"phase_1"},{"name":"ASP2409","genericName":"ASP2409","slug":"asp2409","indication":"Other","status":"phase_1"},{"name":"ASP2998","genericName":"ASP2998","slug":"asp2998","indication":"Other","status":"phase_1"},{"name":"ASP4058","genericName":"ASP4058","slug":"asp4058","indication":"Other","status":"phase_1"},{"name":"ASP4132","genericName":"ASP4132","slug":"asp4132","indication":"Other","status":"phase_1"},{"name":"ASP546C","genericName":"ASP546C","slug":"asp546c","indication":"Other","status":"phase_1"},{"name":"ASP5502","genericName":"ASP5502","slug":"asp5502","indication":"Other","status":"phase_1"},{"name":"ASP6981","genericName":"ASP6981","slug":"asp6981","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"neuroscience","drugs":[{"name":"ASKP1240","genericName":"ASKP1240","slug":"askp1240","indication":"Relapsed or refractory follicular lymphoma","status":"phase_2"},{"name":"ASP1650","genericName":"ASP1650","slug":"asp1650","indication":"Advanced solid tumors (in combination with checkpoint inhibitors)","status":"phase_2"},{"name":"ASP2215","genericName":"ASP2215","slug":"asp2215","indication":"Non-small cell lung cancer with ALK rearrangement","status":"phase_2"},{"name":"LoDAC (Low Dose Cytarabine)","genericName":"LoDAC (Low Dose Cytarabine)","slug":"lodac-low-dose-cytarabine","indication":"Myelodysplastic syndrome (MDS)","status":"phase_3"},{"name":"enfortumab vedotin (EV)","genericName":"enfortumab vedotin (EV)","slug":"enfortumab-vedotin-ev","indication":"Locally advanced or metastatic urothelial cancer","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"ASP5541","genericName":"ASP5541","slug":"asp5541","indication":"Inflammatory and autoimmune disorders (specific indications under investigation in phase 2)","status":"phase_2"},{"name":"ASP1707","genericName":"ASP1707","slug":"asp1707","indication":"Treatment of autoimmune diseases","status":"phase_2"},{"name":"ASP4345","genericName":"ASP4345","slug":"asp4345","indication":"Treatment of autoimmune hemolytic anemia","status":"phase_2"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ASP0819","genericName":"ASP0819","slug":"asp0819","indication":"Treatment of relapsing forms of multiple sclerosis","status":"phase_2"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"ASP0113","genericName":"ASP0113","slug":"asp0113","indication":"Prevention of cytomegalovirus (CMV) reactivation in CMV-seropositive recipients of hematopoietic stem cell transplantation","status":"phase_3"}]}],"pipeline":[{"name":"Tacrolimus immediate release","genericName":"Tacrolimus immediate release","slug":"tacrolimus-immediate-release","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AGS15E","genericName":"AGS15E","slug":"ags15e","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP0819","genericName":"ASP0819","slug":"asp0819","phase":"phase_2","mechanism":"ASP0819 is a small molecule inhibitor of the PI3K delta subunit.","indications":["Treatment of relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"ASP0892","genericName":"ASP0892","slug":"asp0892","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1240","genericName":"ASP1240","slug":"asp1240","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP5354","genericName":"ASP5354","slug":"asp5354","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP5541","genericName":"ASP5541","slug":"asp5541","phase":"phase_2","mechanism":"ASP5541 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.","indications":["Inflammatory and autoimmune disorders (specific indications under investigation in phase 2)"],"catalyst":""},{"name":"ASP7517","genericName":"ASP7517","slug":"asp7517","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ASP8082","genericName":"ASP8082","slug":"asp8082","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP9801","genericName":"ASP9801","slug":"asp9801","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"isavuconazonium sulfate - oral","genericName":"isavuconazonium sulfate - oral","slug":"isavuconazonium-sulfate-oral","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"14C-labeled gilteritinib","genericName":"14C-labeled gilteritinib","slug":"14c-labeled-gilteritinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASKP1240","genericName":"ASKP1240","slug":"askp1240","phase":"phase_2","mechanism":"ASKP1240 is a small molecule inhibitor of the PI3Kδ enzyme.","indications":["Relapsed or refractory follicular lymphoma","Relapsed or refractory marginal zone lymphoma"],"catalyst":""},{"name":"ASP0113","genericName":"ASP0113","slug":"asp0113","phase":"phase_3","mechanism":"ASP0113 is a therapeutic vaccine that stimulates the immune system to recognize and eliminate cells infected with cytomegalovirus (CMV).","indications":["Prevention of cytomegalovirus (CMV) reactivation in CMV-seropositive recipients of hematopoietic stem cell transplantation","Prevention of CMV reactivation in solid organ transplant recipients"],"catalyst":""},{"name":"ASP015K IR","genericName":"ASP015K IR","slug":"asp015k-ir","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP0892 Intradermal","genericName":"ASP0892 Intradermal","slug":"asp0892-intradermal","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP0892 Intramuscular","genericName":"ASP0892 Intramuscular","slug":"asp0892-intramuscular","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1002","genericName":"ASP1002","slug":"asp1002","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1570","genericName":"ASP1570","slug":"asp1570","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1617","genericName":"ASP1617","slug":"asp1617","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1650","genericName":"ASP1650","slug":"asp1650","phase":"phase_2","mechanism":"ASP1650 is a selective antagonist of the prostaglandin E receptor EP4, which reduces inflammatory signaling and immune suppression in the tumor microenvironment.","indications":["Advanced solid tumors (in combination with checkpoint inhibitors)"],"catalyst":""},{"name":"ASP1707","genericName":"ASP1707","slug":"asp1707","phase":"phase_2","mechanism":"ASP1707 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","indications":["Treatment of autoimmune diseases"],"catalyst":""},{"name":"ASP2138","genericName":"ASP2138","slug":"asp2138","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP2215","genericName":"ASP2215","slug":"asp2215","phase":"phase_2","mechanism":"ASP2215 is a selective and potent inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase.","indications":["Non-small cell lung cancer with ALK rearrangement","Ceritinib-resistant non-small cell lung cancer with ALK rearrangement"],"catalyst":""},{"name":"ASP2390","genericName":"ASP2390","slug":"asp2390","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ASP2408","genericName":"ASP2408","slug":"asp2408","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP2409","genericName":"ASP2409","slug":"asp2409","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP2998","genericName":"ASP2998","slug":"asp2998","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP4058","genericName":"ASP4058","slug":"asp4058","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP4132","genericName":"ASP4132","slug":"asp4132","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP4345","genericName":"ASP4345","slug":"asp4345","phase":"phase_2","mechanism":"ASP4345 is a small molecule inhibitor of the PI3K delta subunit.","indications":["Treatment of autoimmune hemolytic anemia"],"catalyst":""},{"name":"ASP546C","genericName":"ASP546C","slug":"asp546c","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP5502","genericName":"ASP5502","slug":"asp5502","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP6981","genericName":"ASP6981","slug":"asp6981","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"LoDAC (Low Dose Cytarabine)","genericName":"LoDAC (Low Dose Cytarabine)","slug":"lodac-low-dose-cytarabine","phase":"phase_3","mechanism":"Low-dose cytarabine is a nucleoside analog that inhibits DNA synthesis by incorporating into DNA and blocking cell division, primarily affecting rapidly dividing hematopoietic cells.","indications":["Myelodysplastic syndrome (MDS)","Acute myeloid leukemia (AML) in elderly patients unfit for intensive chemotherapy"],"catalyst":""},{"name":"enfortumab vedotin (EV)","genericName":"enfortumab vedotin (EV)","slug":"enfortumab-vedotin-ev","phase":"phase_3","mechanism":"Enfortumab vedotin is a monoclonal antibody-drug conjugate that targets Nectin-4, a protein highly expressed on the surface of certain cancer cells.","indications":["Locally advanced or metastatic urothelial cancer","Locally advanced or metastatic non-small cell lung cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQSTljVXdEZDFkXzFGMnpDTVZLaEhtRFlic0NKbnhWcUtQTXBnMTZ6QW1JNzRIUmxqZ1RMTXJVS1BXSkliMUFIQzcxREpha3VEczZhWkp1WUFXRkRjRDliOU9LZnduUVlPN2dzU3N2WF9lYVp3Z29odGY1VFBEbDhDMmpDTWo2YlBQelZ5cWh0Q1phUDZycUhqcmZPdlBWZThLVVFoeTFHbHFyQmdoWTRpa3BQaUpYbGNfWm9fOVJkSDNQUUk?oc=5","date":"2026-02-24","type":"deal","source":"Pharmaceutical Executive","summary":"Astellas Pharmaceuticals Enters $1.7 Billion Global Collaboration with Vir Biotechnology to advance PSMA-targeting PRO-XTEN - Pharmaceutical Executive","headline":"Astellas Pharmaceuticals Enters $1.7 Billion Global Collaboration with Vir Biotechnology to advance PSMA-targeting PRO-X","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQemN1Ui1UMWRnNk5yZFowT2k3cnFuTlBjSVZFazdxLVdfOHhtYUk1RWF3Z2RwaC1WOGtGMHBuLVBpSFg3dXNEM1Z0bnJOOHlRM3hjMjZYT0RPMWQ3b0RieGMwc0FkSDNEb2E1MGVHYTE2V3d4VVdWNFhfSTdEQ1RibHo1alN6VGI3dlVWdlJja0lyVWl0ejJv?oc=5","date":"2026-02-24","type":"deal","source":"BioWorld News","summary":"Astellas and Vir in $1.3B deal for CD3 T-cell engager - BioWorld News","headline":"Astellas and Vir in $1.3B deal for CD3 T-cell engager","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxORF9RRThsQURzTFlWNWgtczhFODBjUXFQQmZVYnZMZVRzTHAwcnFmMVExLUVSWGRPa2tPRk9ralB1VkJ2TG9TREEyVlUweDBHc0VGbk1UVlhxMlkxVzRsTnFBZWw3cVZyMG4zeXZwMXA0cWJtU0tadFlkM0JjU1d2VGt3aHA3QU1aZ3Q1U2NmcnltRmNFSEZwOGxBNUhzNXIxb2p3NDUzOTFSR0ljLUNKazRlYURNbkdYdkJwQTZKUQ?oc=5","date":"2026-02-24","type":"deal","source":"Fierce Biotech","summary":"Evinova reels in AI clinical development deals with Astellas and AstraZeneca - Fierce Biotech","headline":"Evinova reels in AI clinical development deals with Astellas and AstraZeneca","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxPU0ZkR2NXMktwRkZyRnpuTExuNE1zNjRpSmJzQzB0N0NITksxdkU1VnRlZWlxX3pBMjZqdE8yZzJaNDBBdTR6d0g5ekc3OENDeHY5TExNZ3pmOXdPenU0S3VveW9YUm1LRHluRmRHVHhCRFBfNlBzc3lsV3pDcWJnczFuNUc5c0l6Q0Y4eHgwTU8yU0dsRHlXc1lOMGc5U21OMHFXZWJSU0VrSF94SktIMGtvLXY2NTB2cWZ5OFczd0QtNUhvUDZmM1RueVZxR21jaTZlTkppdGRXWHVBWEItNUo2Vjl6T1JuRDJoRkJVUGVEWGRRNU9HUUFTdEZWcFdqa0ppWVM0OG15VmZxc29TeU1DRnNwd1lJSjdIMWJtakpHSkg5QmRoaUxaZS1udnVwZjJkQklTRjg5UldiY2diSEtuVHJrVXcyT2E2TlpoYXYzREZM?oc=5","date":"2026-02-23","type":"deal","source":"PR Newswire","summary":"Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer - PR Newswire","headline":"Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxNUjF4QVR6a21udU1ybVFhdlRsczd6Ry1lZmVkTVhKdTVlc2V0WE8xNGJZYWRWSFZCeEdySzAteE9jRHd6ZU42eC1LYVpzX1pKbGVUUWJDVUhCWHlwUnFXeW9OY0FRdHlSc0xQdXlQNzA2X2JVNzhDUzNuSkkxTGNtRVZteHFweFlJX2VOSzlwTGt6M0JhSWVFTDNFMm96RlBDUkpSc1pQQ1ozQk1WQ05MZ1VZcV8wVXFjWW9yUWlEVWgzQlB2am9GbWVYUmQyUHJvQThwTEppNGU0b3hHUkdCUXJUTEo3VW5GeHktZGU0SGxheFZjaWtTT2VJQksxSFMwclI1Z1BUT08xS0pGWHRpd3cxbERlb0t5ZVdvT09RT05Yblh5OFZJU3JabUt1RmFkWkhTX3FjUC1NcV9QdWxyMXM1NmVNMS1a?oc=5","date":"2026-02-18","type":"deal","source":"Business Wire","summary":"Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development - Business Wire","headline":"Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native P","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-10","type":"patent","source":"The Hindu","summary":"Lupin settles patent infringement dispute with Astellas, to continue selling overactive bladder drug Mirabegron - The Hindu","headline":"Lupin settles patent infringement dispute with Astellas, to continue selling overactive bladder drug Mirabegron","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOTnA0OXNwOXp1ZHozX0VjaUUtSkRhYmtqc2FUS3M2SkJkSEVzSXlWY2VNemJYYmtyMC00Sm0yY3huMzRoSy1CYjlLNFEyMVIwOExSRVBmTlBRZlhGMUJPdlJmeGk3elRaclZFUDhfWnIyVXlWeVBSeVNHMU56MlZycW0zR2dNRUg2NG92cWJURWpqQlA5NElQV1NyMmluNW9nVVRYa3dwWFlxOEhubVdyVG0tQ0UwVW1IX3BFVGVZanpZUdIBxwFBVV95cUxNWGpabzVVOWR6Y29LZlgzNGh4SXJESXhjN0hZSGZvT2YxSGtQMGpKVUg5MVpOQ0JvQUs4b0NOYXNUMGQzR1lGb202YUZIU2Z3S1puQmFqOEdMblZGd09aSDREWFloVDdmYzRtRDgwa2ZUeVFVRENGVG5IcjFrNU5pajFZYjhZa0xOV1MwN0J3VE1lOXpiZVJZVXRKWGx3X1duNmd4MU5KZFdWckhhVjA5cF93LXFIbm1CRjhiYjVxY0dnY3dvV29N?oc=5","date":"2026-02-10","type":"patent","source":"Business Standard","summary":"Lupin settles patent dispute with Astellas - Business Standard","headline":"Lupin settles patent dispute with Astellas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxORGpVMFV2VDVpcTFUV2VLcEVRek8yaUx5dDAySlBXOE9qSW5BQzAyalphQlZ2NmRJeGt6VlBRb01jaFFhSUN5RTRhcUNwcnRYeDZpZFNNSGJQckhiZHZ4RmJvUzlBN1hwdXUyVVVGUDl6N2VkTVZRTFIxdkJ0YkZZZGZLNjIzb1NvNU95SHk2aVBBakl5R0VzWTJZSnJNWkZHaHc1TjVYUmVxbDRGbUtVSnN3NllDLUtmMXBVYU5nQQ?oc=5","date":"2026-02-09","type":"patent","source":"scanx.trade","summary":"Lupin Settles Patent Dispute with Astellas Pharma for USD 90 Million - scanx.trade","headline":"Lupin Settles Patent Dispute with Astellas Pharma for USD 90 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQNHJoR2ZuTGF0YS00SFZFUFktcGI2c1Q0QWhLN3ZmLXRZckUxLTVtX1BwZU1ZMWtneHVGQmdCYUNMSEpXTHBtTk1aN01UZzNVWEI1aXFIMXVOeEpELXBjaEJlT3dPQWNmNEpWeWZxT1RKREV3SlhlbFFwcHhpVFdyTE9nVDJnand0WTQtRUZNSU8tcnBKbVFibnAzcXJCbHpjbU9JZDBMaw?oc=5","date":"2025-10-18","type":"pipeline","source":"lupin.com","summary":"Lupin Launches Mirabegron Extended-Release Tablets in the United States - lupin.com","headline":"Lupin Launches Mirabegron Extended-Release Tablets in the United States","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOV3NZMzIxTEZncWhOWjB6VHp5cTllZ0E0blZaVnNlSThoa0NqUHJrU2VVdFJCNmZCR2lNWHlrdkZOZzhMajZVMUduVVhDblhENmJwYkhxT3BKOXVrVHVLMk5TV25SSi1YOHB5ZzdBMnFTUXpMQ09BTTZVQ2Z6Vjd4bmxqUE1YVXlneUlXOFVRa0lNMTlzNE5rSjBYZUwtUXdYcXdvdA?oc=5","date":"2025-10-17","type":"pipeline","source":"lupin.com","summary":"Lupin Launches Mirabegron Extended-Release Tablets in the United States - lupin.com","headline":"Lupin Launches Mirabegron Extended-Release Tablets in the United States","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPRV9SOVdLOTZ0Tlk0aF9CMk8wQUJKSTdEbFU1ZTMyRGd3SXFXZW1UdnVMcXg3UmVDaFpVSmo5MDlsa3AyeHRRNU50ejE1RnBFV0dTTm9HTS1yMnBRWGozSnlqVHpkWXNmZWpfblpDaXJ2QmxlaFNkQTFfbl9ITGQ1dXdCdEtBblZ6clpLcVp5R1d0Y1M4V1lNMVc5cnhjanRlbW5SOFU3U0stSTVOcGFJVkJEM3NrdEdOVmZtSWpRWFo5em9lVjFnX3ZkQ1M1NkdsTC1xRTA2UnljbTl1c3hRRTIwV2FGdy1rV2xDbFR3?oc=5","date":"2025-06-13","type":"deal","source":"PR Newswire","summary":"Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan - PR Newswire","headline":"Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE1GOEdLZDRBS0RwRVY3bmlqZW1mZWxFMUZ2UkNQMnlUcDlRMUJ4VXdPaGtPM0FiWmhlYWJzeXlkVE5JaDVncm1pM2hQYTFPWVBOVk8wUDc0cWdxMXpMRlNzT2FCaE1wTHBLdkxR?oc=5","date":"2024-09-18","type":"regulatory","source":"Wiley Online Library","summary":"The role of cardiac acoustic biomarkers in monitoring patients with heart failure: A systematic literature review - Wiley Online Library","headline":"The role of cardiac acoustic biomarkers in monitoring patients with heart failure: A systematic literature review","sentiment":"neutral"}],"patents":[],"drugCount":36,"phaseCounts":{"marketed":1,"phase_1":25,"phase_2":7,"phase_3":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}